Loading…
Based on limited metadata with no full letter text available, the FDA issued a Warning Letter to Banco Vida Corp. on March 4, 2020, regarding biologics products. While the specific violations cannot be detailed due to unavailable subject line information, this communication from the FDA indicates regulatory concerns with the company's biologics operations that required formal enforcement action. The exact nature of the compliance issues and the specific FDA office issuing the letter are not identifiable from the available metadata.